Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04706923 · ClinicalTrials.gov registry record · Phase 2

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

A Phase 2 study of Cytomegalovirus Infection and Adenovirus Infections, sponsored by SymBio Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
52
Enrollment target
11
Study locations

NCT04706923 is a Phase 2 study of Cytomegalovirus Infection and Adenovirus Infections that is actively recruiting participants, run by SymBio Pharmaceuticals. The registered enrollment target is 52 participants, below the 234-participant average among 5 other Cytomegalovirus Infection trials with a reported enrollment target (78% lower). The trial reports 11 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04706923, a Phase 2 study of Cytomegalovirus Infection and Adenovirus Infections, is actively recruiting participants, sponsored by SymBio Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
52 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV

Conditions Studied

Cytomegalovirus Infection Adenovirus Infections

Interventions

  • DRUG BCV

Study Locations (11)

California

  • Research Site - Los Angeles
  • Research Site - Los Angeles
  • Research Site - San Francisco

Illinois

  • Research Site - Chicago

Nebraska

  • University of Nebraska Medical Center - Omaha

North Carolina

  • Research Site - Durham

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Pennsylvania

  • Research Site - Philadelphia

Tennessee

  • St. Jude Children's Research Hospital - Memphis

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2021-08-16
Est. Completion 2026-09-30
Phase Phase 2

Sponsor

SymBio Pharmaceuticals

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04706923

The ClinicalTrials.gov registry entry for NCT04706923 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 234-participant average among 5 other Cytomegalovirus Infection trials with a reported enrollment target (78% lower). The listed sponsor is SymBio Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cytomegalovirus Infection appearing as the primary indexed condition, and to 1 intervention - of which BCV is the first listed.

NCT04706923 reports 11 study locations spanning 9 distinct geographic areas - top geographies include California, Illinois, Nebraska.

Frequently Asked Questions

What is clinical trial NCT04706923 about?

NCT04706923 is a clinical study titled "A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection". The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV

What is the current status of trial NCT04706923?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2021-08-16. Estimated completion is 2026-09-30.

What conditions does trial NCT04706923 study?

This clinical trial studies the following conditions: Cytomegalovirus Infection, Adenovirus Infections.

What interventions are being tested in trial NCT04706923?

The interventions under investigation include: BCV (DRUG).

Who is sponsoring clinical trial NCT04706923?

This trial is sponsored by SymBio Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04706923 being conducted?

This trial has 11 study locations across California, Illinois, Nebraska, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cytomegalovirus Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cytomegalovirus Infection

All registered trials for this condition

Adenovirus Infections

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.